Global investment firm KKR on Monday likened its acquisition of Hyderabad-based Ramky Enviro Engineers Limited (REEL) to the Gland Pharma deal concluded last year by Chinese company Fosun Pharma as the existing promoters are likely to play a central role in building the business.
"This is a little bit like Gland (Gland Pharma deal) in a way that you are taking control of the company and working with the existing management to try and take it to a new level," KKR India member and CEO Sanjay Nayar said as he sought to place the future role of existing promoters on